Here is a breakdown of the 10 drugs employer-sponsored health plans paid the most for in 2017:
1. Humira ($4.9 billion)
2. Enbrel ($2.4 billion)
3. Copaxone ($1.2 billion)
4. Tecfidera ($1.1 billion)
5. Harvoni ($1 billion)
6. Truvada ($900 million)
7. Stelara ($900 million)
8. Vyvanse ($900 million)
9. Lantus Solostar ($800 million)
10. Gilenya ($700 million)
Read the full report here.
More articles on pharmacy:
How hospitals can better align the pharmacy to achieve its strategic goals
Google sister-company Verily partners with big pharma for clinical trials
Merck’s Keytruda fails late-stage trial as standalone treatment for breast cancer